DE60327793D1 - Modulation der s6-kinaseaktivität zur behandlung von adipositas - Google Patents

Modulation der s6-kinaseaktivität zur behandlung von adipositas

Info

Publication number
DE60327793D1
DE60327793D1 DE60327793T DE60327793T DE60327793D1 DE 60327793 D1 DE60327793 D1 DE 60327793D1 DE 60327793 T DE60327793 T DE 60327793T DE 60327793 T DE60327793 T DE 60327793T DE 60327793 D1 DE60327793 D1 DE 60327793D1
Authority
DE
Germany
Prior art keywords
adipositas
modulation
treatment
kinase activity
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327793T
Other languages
English (en)
Inventor
Francesca Frigerio
Stefano Fumagalli
Sara C Kozma
Melanie Sticker-Jantscheff
George Thomas
Sung Hee Um
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0224338.4A external-priority patent/GB0224338D0/en
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Application granted granted Critical
Publication of DE60327793D1 publication Critical patent/DE60327793D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60327793T 2002-10-18 2003-10-17 Modulation der s6-kinaseaktivität zur behandlung von adipositas Expired - Lifetime DE60327793D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0224338.4A GB0224338D0 (en) 2002-10-18 2002-10-18 Modulation of S6 kinase activity for the treatment of obesity
US49722703P 2003-08-22 2003-08-22
PCT/EP2003/011554 WO2004035815A1 (en) 2002-10-18 2003-10-17 Modulation of s6 kinase activity for the treatment of obestiy

Publications (1)

Publication Number Publication Date
DE60327793D1 true DE60327793D1 (de) 2009-07-09

Family

ID=32109253

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327793T Expired - Lifetime DE60327793D1 (de) 2002-10-18 2003-10-17 Modulation der s6-kinaseaktivität zur behandlung von adipositas

Country Status (7)

Country Link
EP (1) EP1556505B1 (de)
JP (1) JP2006502744A (de)
AT (1) ATE432359T1 (de)
AU (1) AU2003282035A1 (de)
DE (1) DE60327793D1 (de)
ES (1) ES2328033T3 (de)
WO (1) WO2004035815A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
DE602006006578D1 (de) * 2006-10-04 2009-06-10 Agronomique Inst Nat Rech Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen
WO2013017656A1 (en) * 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510327A (ja) * 1996-03-12 2000-08-15 スミスクライン・ビーチャム・コーポレイション 医薬的に活性な化合物の同定方法
ATE498014T1 (de) * 1998-08-04 2011-02-15 Ludwig Inst Cancer Res Identifizierung und funktionelle charakterisierung einer ribosomalen s6 proteinkinase
WO2000066721A2 (en) * 1999-04-30 2000-11-09 Beth Israel Deaconess Medical Center Decreasing adipose mass by altering rsk2 activity
US20030143656A1 (en) * 1999-12-02 2003-07-31 Dario Alessi Protein kinase regulation

Also Published As

Publication number Publication date
ATE432359T1 (de) 2009-06-15
EP1556505A1 (de) 2005-07-27
AU2003282035A1 (en) 2004-05-04
ES2328033T3 (es) 2009-11-06
EP1556505B1 (de) 2009-05-27
JP2006502744A (ja) 2006-01-26
WO2004035815A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60202727D1 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DE69633566D1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE369755T1 (de) Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE345793T1 (de) Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE370738T1 (de) Verwendung von eplerenon zur behandlung von restenose
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN